US FDA Warns Foreign Manufacturers Of OTC Analgesics For Monograph Non-Compliance
Executive Summary
Malaysia-based Furley Bioextracts and Honduras-based Laboratorio Pharma International receive warning letters from the US FDA following import alerts in May and June for marketing products as OTC analgesic drugs without complying with controlling monograph conditions.
You may also be interested in...
OTC Topicals After Bite, Itch Eraser Are Irritants To US FDA Monograph, GMP Regulations
Adventure Ready Brands is the second small firm warned recently by FDA about manufacturing and marketing products labeled as nonprescription drugs but noncompliant with relevant OTC drug monographs and about GMP violations.
OTC Ear Care Firm Eosera Gets Earful From US FDA On Pain And Itch Remedies, GMP Compliance
Eosera has removed its Ear Pain MD and Ear Itch MD products from e-commerce pages on its website following FDA's warning letter. The warning identifying the pain and itch products as unapproved new drugs also states that a January inspection of the firm’s facility found GMP violations.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.